Literature DB >> 12912960

Gene expression profiling of malignant mesothelioma.

Sunil Singhal1, Rainer Wiewrodt, Liliana D Malden, Kunjlata M Amin, Kimberly Matzie, Joseph Friedberg, John C Kucharczuk, Leslie A Litzky, Steven W Johnson, Larry R Kaiser, Steven M Albelda.   

Abstract

PURPOSE: Malignant mesothelioma is a uniformly fatal cancer of the pleural and peritoneal spaces. Several challenging clinical problems include poor understanding of the pathophysiology, inaccurate diagnosis from tissue samples, and unsuccessful treatment strategies. The purpose of this study was to use microarray analysis to identify specific gene expression changes in mesothelioma compared with normal mesothelium. EXPERIMENTAL
DESIGN: We performed gene expression analysis on mesothelioma tissue specimens from 16 patients and compared these to 4 control pleural tissue samples using cDNA microarray filters with 4132 clones. Multiple normalization and analysis approaches were used. Quantitative reverse transcription-PCR and immunohistochemistry were used to validate results.
RESULTS: Genes (166) were significantly up-regulated, and 26 were down-regulated. Validation of 18 genes using real-time PCR confirmed array predictions in every case. Analysis revealed activation of several key pathways including genes involved in glucose metabolism, mRNA translation, and cytoskeletal remodeling. Expression profiling identified processes likely responsible for 18-fluoro-2-deoxy-glucose uptake and tumor localization by positron emission tomography, and a role for hypoxia-inducible factor-1 was suggested. Potentially important up-regulated genes included gp96, lung resistance-related protein, galectin-3 binding protein, the M(r) 67,000 laminin receptor (on tumor vessels), and voltage-dependent anion channels. Prospective testing using reverse transcription-PCR confirmed up-regulation of these novel markers.
CONCLUSIONS: Expression profiling revealed marked up-regulation of energy, protein translation, and cytoskeletal remodeling pathways in mesothelioma. Additional genes that could be important in our understanding of the pathogenesis of mesothelioma, aiding in diagnosis, or improving targets for therapy were also identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12912960

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

Review 1.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

2.  Molecular biology of malignant mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease.

Authors:  K Schreiter; M Hausmann; T Spoettl; U G Strauch; F Bataille; J Schoelmerich; H Herfarth; W Falk; G Rogler
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

4.  Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Authors:  Gavin J Gordon; Graham N Rockwell; Roderick V Jensen; James G Rheinwald; Jonathan N Glickman; Joshua P Aronson; Brian J Pottorf; Matthew D Nitz; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 5.  Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

Authors:  Elisa Barone; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.

Authors:  S Cedrés; M A Montero; E Zamora; A Martínez; P Martínez; L Fariñas; A Navarro; D Torrejon; A Gabaldon; S Ramon Y Cajal; E Felip
Journal:  Clin Transl Oncol       Date:  2013-12-10       Impact factor: 3.405

7.  Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.

Authors:  Sanja Dacic; Hannelore Kothmaier; Stephanie Land; Yongli Shuai; Iris Halbwedl; Patrizia Morbini; Bruno Murer; Camilla Comin; Françoise Galateau-Salle; Funda Demirag; Handan Zeren; Richard Attanoos; Alan Gibbs; Philip Cagle; Helmut Popper
Journal:  Virchows Arch       Date:  2008-10-29       Impact factor: 4.064

8.  Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.

Authors:  Solange Romagnoli; Ester Fasoli; Valentina Vaira; Monica Falleni; Caterina Pellegrini; Anna Catania; Massimo Roncalli; Antonio Marchetti; Luigi Santambrogio; Guido Coggi; Silvano Bosari
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

9.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

Review 10.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.